NOVALIQ GmbH, founded in 2007, is a specialty pharmaceutical company located in the Heidelberg Technology Park, Germany focused on the development of innovative water-free ophthalmics.
Our mission is to transform Active Pharmaceutical Ingredients (APIs) into highly effective ocular therapeutics for both the front and the back of the eye.
NovaTears®, a first-in-class, water-free product with a novel mode of action for treatment of evaporative dry eye is registered and marketed in Europe.
The most advanced Rx development is CyclASol® for the treatment of moderate to severe dry eye disease. Recent reported phase 2 data confirmed that CyclASol® has demonstrated a superior outcome and an earlier onset of action when compared head to head vs. Restasis™.
All product developments are based on Novaliq’s proprietary drug delivery technology called EyeSol® which enhances the topical bio-availability, stability and safety of traditionally unstable APIs improving the delivery, efficacy and convenience of treatments for ocular surface diseases, including dry eye, through preservative-free and multi-dose formulations.